Mikhail N Kosiborod
Overview
Explore the profile of Mikhail N Kosiborod including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
225
Citations
7867
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Docherty K, McDowell K, Welsh P, Petrie M, Anand I, Berg D, et al.
JACC Heart Fail
. 2025 Mar;
PMID: 40088234
Background: Inflammation may play an important pathophysiological role in the development and progression of heart failure (HF). Interleukin (IL)-6 is a circulating cytokine and is the main regulator of the...
2.
Inciardi R, Lu H, Claggett B, Desai A, Jhund P, Lam C, et al.
JACC Heart Fail
. 2025 Mar;
PMID: 40047763
Background: Patients with severe heart failure (HF) experience debilitating clinical symptoms and worse cardiovascular (CV) outcomes with an excess mortality risk. Objectives: The authors aimed to assess the prevalence, CV...
3.
Kovesdy C, Ebert N, Vizcaya D, Walsh M, Kosiborod M, Layton J, et al.
Nephron
. 2025 Feb;
:1-26.
PMID: 40015260
Introduction: In 2021, finerenone - a novel, selective non-steroidal mineralocorticoid receptor antagonist - was approved in the US to treat adults with CKD and T2D This study aimed to describe...
4.
Aggarwal R, Bhatt D, Szarek M, Cannon C, Leiter L, Inzucchi S, et al.
Lancet Diabetes Endocrinol
. 2025 Feb;
PMID: 39961315
Background: Sodium-glucose co-transporter (SGLT)-2 inhibitors have shown consistent benefit in improving heart failure-related outcomes but not ischaemic cardiovascular events such as myocardial infarction or stroke. We assessed if the dual...
5.
Yang M, Kondo T, Talebi A, Jhund P, Docherty K, Claggett B, et al.
JACC Heart Fail
. 2025 Feb;
13(2):277-292.
PMID: 39909641
Background: The value of generic quality of life (QoL) instruments in heart failure (HF) is uncertain. Objectives: In this study, the authors sought to quantify individual dimension scores and the...
6.
Davies M, van der Meer P, Verma S, Patel S, Chinnakondepalli K, Borlaug B, et al.
Lancet Diabetes Endocrinol
. 2025 Jan;
13(3):196-209.
PMID: 39848268
Background: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF...
7.
Ambrosy A, Sauer A, Patel S, Windsor S, Borlaug B, Husain M, et al.
ESC Heart Fail
. 2024 Dec;
PMID: 39716939
Aims: Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve health status and outcomes in the setting of heart failure (HF) across the range of ejection fraction (EF). Baseline kidney disease is common in...
8.
Peterson B, Bhatt D, Ballantyne C, de Lemos J, Rosenson R, Kosiborod M, et al.
Int J Cardiol
. 2024 Dec;
421():132916.
PMID: 39701461
Background: Patients with a history of coronary revascularization are at a higher risk for subsequent cardiovascular events and all-cause mortality. Lowering LDL-cholesterol (LDL-C) levels post-revascularization significantly reduces these risks. Methods:...
9.
10.
Khadke S, Kumar A, Bhatti A, Dani S, Al-Kindi S, Nasir K, et al.
J Card Fail
. 2024 Dec;
PMID: 39667523
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) promote weight loss and improve heart failure-related symptoms, quality of life, and functional capacity in patients with obesity and heart failure with preserved ejection...